A Day of Reckoning for Aging Facilities: Is It Time to Invest in Change?
This article was originally published in The Gold Sheet
Executive Summary
With its acquisition of Hospira, Pfizer joins the ranks of pharmaceutical companies struggling to eke out a profit from aging sterile injectables facilities without shutting them down for badly needed upgrades for fear of triggering additional drug shortages. Meanwhile, flexible, modular next-generation facilities that could add capacity where needed are on the horizon.